DelRicht Research is proud to highlight the outstanding performance of our site teams across Atlanta, Gulfport, New Orleans, and Tulsa in a recent Phase 3 clinical trial for migraine. Designed to evaluate the safety and efficacy of an investigational therapy in adults ages 18-70, the study enrolled 400 participants across 66 sites nationwide between March and July 2025.

Exceeding Expectations in Migraine Research

DelRicht was expected to enroll 24 participants across four sites. By study close, our teams collectively enrolled 36 qualified participants, reaching 150% of our expected enrollment goal. This achievement underscores the strength of DelRicht’s embedded research model and the collaboration among experienced investigators and dedicated site teams.

Leading the way was Dr. Robert Springer of Atlanta, GA, whose site ranked as the #2 top enroller studywide. He was joined by Dr. Sean Kerby (Gulfport, MS), Dr. Patrick Dennis (New Orleans, LA), and Dr. Melita Tate (Tulsa, OK), each contributing to a coordinated, high-performing network that delivered consistent results and dependable data quality.

Overcoming Operational Challenges with Precision

Like many migraine studies, this trial presented challenges that demanded both technical rigor and patient support. Each participant was required to provide verified medical records confirming diagnosis, a step that often introduces delays in screening and eligibility confirmation. In addition, maintaining accurate daily eDiary entries, a cornerstone of migraine research, posed ongoing compliance challenges across study sites.

DelRicht addressed these complexities through two key strategies:

1. Leveraging a verified participant database. Our teams utilized a pre-qualified database of prior migraine participants with confirmed medical documentation, streamlining eligibility verification and accelerating enrollment timelines.

2. Enhancing compliance through proactive monitoring. Coordinators conducted daily eDiary reviews, supported by automated text reminders and a 24/7 study support line to assist participants and ensure data accuracy.

These solutions strengthened participant engagement and data integrity across all sites.

Rapid Activation and Coordinated Execution

DelRicht’s four participating sites completed their first patients screened within an average of just 3.5 days from activation, demonstrating exceptional readiness and operational coordination. This rapid start-up was made possible through DelRicht’s centralized processes for regulatory submissions, contract execution, and cross-site communication, allowing investigators to focus on participant experience and study precision.

Partnering for Progress in Migraine Research

Migraine is one of the world’s most common and disabling neurological conditions, affecting millions of adults each year. Research like this plays a vital role in expanding access to new treatment options and improving quality of life for those living with chronic headache disorders.

The success of this trial reflects DelRicht’s continued commitment to offering research as a care option and to partnering with sponsors and CROs who value agility, quality, and performance.

Highlights

– 36 participants enrolled (150% of expected goal)

– Average of 3.5 days from activation to first patient screened

– Dr. Springer recognized as #2 top enroller studywide

– Four sites across GA, MS, LA, and OK contributing coordinated success

DelRicht Research remains a trusted partner in advancing migraine research through operational excellence, experienced investigators, and patient-centered innovation. To learn more about partnering with DelRicht, visit www.DelRichtResearch.com or contact us to explore collaboration opportunities.